Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pediatrics

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1542/peds.2013-0982PMID 24127479
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants.

  2010cited by this paper
• Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life

  2010cited by this paper
• The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

  2010cited by this paper
• Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

  2007cited by this paper
• Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study

  2005cited by this paper
• Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.

  2005cited by this paper
• Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection

  2004cited by this paper
• [Humanized respiratory syncytial virus monoclonal antibody].

  2002cited by this paper
• Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

  2000cited by this paper
• Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.

  1999cited by this paper
• Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

  1999cited by this paper
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

  1998cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

  1997cited by this paper

• Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants

  2026cites this paper
• The association between early-life respiratory infections and childhood asthma: a meta-analytic perspective.

  2026cites this paper
• Respiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter Study

  2025cites this paper
• Understanding and Managing Viral-Induced Wheezing in Children: The Role of Parental Knowledge

  2025cites this paper
• Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

  2025cites this paper
• Moderate-to-late prematurity: understanding respiratory consequences and modifiable risk factors

  2025cites this paper
• Exploring parental awareness and willingness to use monoclonal antibodies for respiratory syncytial virus prevention

  2025influential citation
• Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children

  2025cites this paper
• Effects of COVID-19 pandemic–associated reduction in respiratory infections on infantile asthma development

  2024cites this paper
• Chapter 9 Specificity and Management for Asthma in Infant and Preschool Children

  2024cites this paper
• A Community-Guided Approach to Bronchiolitis: A Needs Assessment and Illness Perception Study

  2024cites this paper
• Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region.

  2024cites this paper
• Assessing the long-term economic impact of wheezing episodes after severe RSV disease in children from Argentina: a cost of illness analysis

  2024cites this paper
• Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

  2023influential citation
• Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10‐year follow‐up study

  2023cites this paper
• Azithromycin for acute bronchiolitis and wheezing episodes in children – a systematic review with meta-analysis

  2023cites this paper
• Are Babies Born Preterm High-Risk Asthma Candidates?

  2023cites this paper
• Exacerbated lung inflammation following secondary RSV exposure is CD4+ T cell-dependent and is not mitigated in infant BALB/c mice born to PreF-vaccinated dams

  2023cites this paper
• A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age

  2023cites this paper
• Update on virus-induced asthma exacerbations

  2023cites this paper
• Understanding the increased susceptibility to asthma development in preterm infants

  2023cites this paper
• Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review

  2022influential citation
• World Journal of Critical Care Medicine

  2022cites this paper
• RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

  2022cites this paper
• Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective.

  2022cites this paper
• Advances in Pathogenesis and Treatment of Asthmatic Bronchial Pneumonia in Children

  2022cites this paper
• Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions

  2022cites this paper
• An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma

  2022cites this paper
• Association between early viral lower respiratory tract infections and subsequent asthma development

  2022cites this paper
• Disease burden of respiratory syncytial virus infection in the pediatric population in Japan.

  2021cites this paper
• Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

  2021cites this paper
• Persistent Airway Hyperresponsiveness Following Recovery from Infection with Pneumonia Virus of Mice

  2021cites this paper
• A post-incorporation study on the use of palivizumab in the Brazilian public health system.

  2021cites this paper
• Socioeconomic Impact of RSV Hospitalization

  2021cites this paper
• Association between early viral LRTI and subsequent wheezing development, a meta-analysis and sensitivity analyses for studies comparable for confounding factors

  2021cites this paper
• Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO-defined non-severe pneumonia and wheeze.

  2021cites this paper
• Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics

  2021cites this paper
• Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis

  2020cites this paper
• Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.

  2020cites this paper
• Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma?

  2020cites this paper
• Early-Life Respiratory Syncytial Virus Infection, Trained Immunity and Subsequent Pulmonary Diseases

  2020cites this paper
• Pulmonary function sequelae after respiratory syncytial virus lower respiratory tract infection in children: A systematic review

  2020cites this paper
• A Durable Relationship: Respiratory Syncytial Virus Bronchiolitis and Asthma past Their Golden Anniversary

  2020influential citation
• Association of early viral lower respiratory infections and subsequent development of atopy, a systematic review and meta-analysis of cohort studies

  2020cites this paper
• Palivizumab following extremely premature birth does not affect pulmonary outcomes in adolescents.

  2020cites this paper
• Up-to-date role of biologics in the management of respiratory syncytial virus

  2020cites this paper
• Azithromycin administered for acute bronchiolitis may have a protective effect on subsequent wheezing

  2020cites this paper
• Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting

  2020cites this paper
• Recurrent wheezing during the first 3 years of life in a birth cohort of moderate‐to‐late preterm infants

  2020cites this paper
• Wheezing in preterm infants and children

  2020cites this paper
• RSV Lower Respiratory Tract Illness in Infants of Low- and Middle-income Countries.

  2020cites this paper
• Risk Factors Associated With Bronchiolitis in Puerto Rican Children

  2020cites this paper
• Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade

  2019cites this paper
• The long road to protect infants against severe RSV lower respiratory tract illness

  2019cites this paper
• Resolving the Debate on RSV Prophylaxis in Late Preterm Infants

  2019cites this paper
• Bronchiolites du prématuré tardif et du grand prématuré : incidence, facteurs de risque

  2019cites this paper
• Recurrent wheezing in preterm infants: Prevalence and risk factors.

  2019cites this paper
• TEMPORAL TREND OF HOSPITALIZATIONS FOR ACUTE BRONCHIOLITIS IN INFANTS UNDER ONE YEAR OF AGE IN BRAZIL BETWEEN 2008 AND 2015

  2019cites this paper
• Asthma and viral infections

  2019cites this paper
• Respiratory Syncytial Virus Immunoprophylaxis: Issues in Short-term and Longer-term Impact

  2019cites this paper
• Respiratory syncytial virus in the Western Pacific Region: a systematic review and meta-analysis

  2019cites this paper
• Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO)

  2018cites this paper
• Palivizumab Prophylaxis and Recurrent Wheezing.

  2018cites this paper
• Respiratory viral infections and atopic development: From possible mechanisms to advances in treatment

  2018cites this paper
• Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field

  2018cites this paper
• Childhood Asthma: Is It All About Bacteria and Not About Viruses? A Pro/Con Debate.

  2018cites this paper
• Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?

  2018cites this paper
• RSV infection and respiratory sequelae.

  2018cites this paper
• The Epidemiology of Asthma

  2018cites this paper
• COST EFFECTIVENESS OF PALIVIZUMAB PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS IN PRETERM INFANTS: A NATIONWIDE POPULATION-BASED COHORT STUDY IN TAIWAN

  2018cites this paper
• Academy News

  2018cites this paper
• Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children

  2018cites this paper
• Bronchiolitis in young infants: is it a risk factor for recurrent wheezing in childhood?

  2017cites this paper
• High level of MIP-1α in nasopharyngeal aspirates is a biomarker of recurrent wheezing in children

  2017cites this paper
• Characteristics of infants hospitalized with bronchiolitis at University Hospital of Split between 2011 and 2015

  2017cites this paper
• Passive and active immunization against respiratory syncytial virus for the young and old

  2017influential citation
• Diagnosis, prevention, and management of bronchiolitis in children: review of current controversies.

  2017cites this paper
• Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six‐Year Follow‐up Study

  2017influential citation
• Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

  2017cites this paper
• Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus—Insights in pathogenesis and perspectives for new treatments

  2017cites this paper
• Wheezing, asthma, and atopy in premature infants at 2 years of age.

  2017cites this paper
• Palivizumab Exposure and the Risk of Atopic Dermatitis, Asthma and Allergic Rhinoconjunctivitis: A Cross-National, Population-Based Cohort Study

  2017cites this paper
• Neutralizing epitopes of RSV and palivizumab resistance in Japan.

  2017cites this paper
• Anti‐retroviral antibody FcγR‐mediated effector functions

  2017cites this paper
• Recurrent Wheezing in Childhood and Palivizumab.

  2017cites this paper
• Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus

  2017cites this paper
• Respiratory syncytial virus immunoprophylaxis in high‐risk infants and development of childhood asthma

  2017influential citation
• Viral infection and development of asthma

  2017cites this paper
• Bronchiolitis and asthma: the next step.

  2017cites this paper
• Wheeze after Hospitalization for Respiratory Syncytial Virus Infection in Children

  2017cites this paper
• Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease

  2016cites this paper
• Review of the clinical significance of respiratory virus infections in newborn infants

  2016cites this paper
• Motavizumab, RSV, and subsequent wheezing.

  2016cites this paper
• MIP-1α level in nasopharyngeal aspirates at the first wheezing episode predicts recurrent wheezing.

  2016cites this paper
• Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.

  2016cites this paper
• The Role of Antiviral Strategies for the Prevention of Childhood Asthma

  2016cites this paper
• Clinical Endpoints for RSV Prophylaxis Trials in Infants and Children In Industrialized Countries

  2016cites this paper
• Vaccination against respiratory syncytial virus in pregnancy.

  2016cites this paper
• Have Changing Palivizumab Administration Policies Led to More Respiratory Morbidity in Infants Born at 32-35 Weeks?

  2016cites this paper
• Efficacy and Safety of Salmeterol/fluticasone Combination Therapy in Infants and Preschool Children with Asthma Insufficiently Controlled by Inhaled Corticosteroids

  2016cites this paper